GlaxoSmithKline Covid-19 drug falls short in trial, but may benefit older patients
An experimental rheumatoid arthritis drug being developed by GlaxoSmithKline failed to show a significant benefit in hospitalized patients with Covid-19, the drug maker said Thursday.
However, patients older than 70 were more likely to be free of respiratory failure, a result that GSK plans to test in a new cohort of the study.
“The bottom line is we’re doing a confirmatory cohort study,” said Mark Layton, a medical development lead at GSK. “We accept that subgroups can be misleading.”